• PBS Liposomes: Evidence Gaps in Control Interpretation

  2026-10-13

  PBS Liposomes are described by APExBIO as blank phosphate-buffered saline liposomes intended as a comparator in macrophage depletion studies. However, the supplied literature does not provide a published head-to-head validation of this product, and the cited TRPM3 study addresses ion-channel structure rather than macrophage biology. Interpretation therefore depends on separating documented product identity from independently established evidence about carrier effects, phagocytosis, biodistribution and assay context.

• 5-(N,N-dimethyl)-Amiloride and Sepsis Biology

  2026-10-13

  The available evidence supports moesin as a candidate marker of endothelial injury in sepsis, while the supplied product information describes 5-(N,N-dimethyl)-Amiloride hydrochloride as an inhibitor of selected Na+/H+ exchangers. The cited sepsis study did not evaluate this compound, so any connection between Na+/H+ exchanger signaling and moesin-related endothelial dysfunction remains a research hypothesis rather than a demonstrated therapeutic or diagnostic application.

• Moesin and Endothelial Injury in Sepsis

  2026-10-12

  Chen et al. evaluated circulating moesin as a candidate marker of endothelial injury in sepsis using patient observations, animal models, and human endothelial-cell experiments. The study reports associations between higher moesin and greater illness or lung-injury measures, while cell-silencing results support a possible role for moesin in Rock1/MLC and NF-κB-linked permeability and inflammatory responses. The findings are mechanistically suggestive but do not establish diagnostic performance, causality in patients, or any role for 5-(N,N-dimethyl)-Amiloride hydrochloride.

• AP20187: Evidence, Scope, and Limitations

  2026-10-12

  AP20187 is described by APExBIO as a synthetic, cell-permeable chemical inducer of dimerization for engineered signaling systems. The supplied cancer-biology dissertation provides relevant context on 14-3-3 signaling, ATG9A, and PTOV1, but it does not establish that AP20187 was used or that the compound regulates those proteins.

• BMPSB4 and Autophagy in Corticotroph PitNETs

  2026-10-10

  A 2024 study identified BMPSB4 as a small-molecule agonist of BMP4 signaling that suppresses corticotroph pituitary neuroendocrine tumor models through SMAD1/5/9-associated autophagy. Its findings connect reduced BMP4 activity in Cushing’s disease with tumor-cell inhibition and lower ACTH-related endocrine effects, while remaining preclinical.

• Sorafenib and ATRX: Evidence, Scope, Limits

  2026-10-09

  A source-grounded overview of Sorafenib, also known as BAY-43-9006, covering its multikinase principles, findings in ATRX-deficient high-grade glioma models, evidence strength, interpretation, and limits of applicability.

• DIDS in Chloride Transport and Cancer Research

  2026-10-09

  DIDS is a broad anion-transport research tool whose reported effects span chloride channels, exchangers, vascular signaling, sensory biology, and cancer models. This overview compares supplier-reported activities with the peer-reviewed PAME metastasis study and explains why DIDS should be interpreted as a context-dependent pharmacological probe rather than a selective therapeutic or definitive mechanistic test.

• From NET-DNA Biology to Spatial Signal Strategy

  2026-10-08

  A translational perspective on how tyramide signal amplification can support spatial investigation of NET-DNA, CCDC25, ILC3s, and intestinal epithelial repair—while keeping the evidence boundaries of mouse and in vitro findings clear.

• JXY, TLR4, and M1 Macrophages in CAC

  2026-10-08

  Liu et al. report that Jiedu Xiaozheng Yin limits colitis-associated colorectal cancer in a mouse model while shifting macrophages toward an M1-like phenotype through TLR4-associated signaling. The study’s main contribution is an integrated in vivo and in vitro framework linking tumor burden, macrophage markers, phagocytic activity, and pathway perturbation, while its findings remain preclinical and model-specific.

• Human CBL Deficiency Rewires B Cell Immunity

  2026-10-07

  A 2026 Nature Immunology study uses naturally occurring, leukocyte-restricted CBL loss of function to define how human immune cells respond to impaired ubiquitin-mediated signaling control. The findings reveal a marked B cell phenotype—impaired tolerance, maturation, class switching and immune memory—while human T cell development and function remain comparatively preserved.

• NADPH Oxidase ROS and Arterial Contraction

  2026-10-07

  A study in early postnatal rat arteries places L-type voltage-gated calcium channels downstream of NADPH oxidase-derived reactive oxygen species in adrenergic contraction. Its pharmacological evidence argues against Rho-kinase, PKC, or Src-kinase as the principal mediators of this specific ROS effect, while also indicating that calcium-channel blockade does not suppress ROS generation.

• Chlorpromazine and Hepatic Nanoparticle Evidence

  2026-10-06

  A five-question, source-grounded overview clarifying what a 2026 ACS Nano study shows about PEGylated iron oxide nanoparticle uptake in liver cells—and why those findings should not be interpreted as evidence about chlorpromazine pharmacology or clinical use.

• AZ505 and SMYD2: Evidence in Fibrosis Research

  2026-10-06

  A source-grounded overview of AZ505 as a research tool for studying SMYD2, with emphasis on cisplatin-associated renal fibrosis, epigenetic regulation, evidence strength, and the limits of translating preclinical findings to cancer or clinical applications.

• HBsAg, TBK1, Interferon, and Early Autophagy

  2026-10-05

  A 2025 Cell Death and Disease study identifies a mechanism by which hepatitis B surface antigen redirects TBK1 signaling, weakening type I interferon responses while promoting incomplete autophagy. Its value lies in connecting viral immune evasion with altered TBK1 complex formation, p62 phosphorylation, and impaired autophagosome–lysosome fusion across cellular, animal, and human tissue evidence.

• Moxifloxacin: Research Context and Evidence Limits

  2026-10-05

  A source-grounded overview of Moxifloxacin research uses, reported cellular and metabolic findings, mechanistic context, and the limitations of comparing vendor-reported observations with peer-reviewed evidence on related topoisomerase inhibitors.

8546 records 1/570 page Next 12345 下5页 Last page